Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

1.62USD
15 Oct 2018
Change (% chg)

-- (--)
Prev Close
$1.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
146,862
52-wk High
$11.41
52-wk Low
$0.83

Latest Key Developments (Source: Significant Developments)

Gemphire Provides Update On Development Of Gemcabene
Monday, 6 Aug 2018 04:01pm EDT 

Aug 6 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE PROVIDES UPDATE ON DEVELOPMENT OF GEMCABENE.GEMPHIRE THERAPEUTICS INC - FDA REQUESTS COMPANY PROVIDE ADDITIONAL DATA REGARDING PARTIAL CLINICAL HOLD.GEMPHIRE THERAPEUTICS INC - COMPANY CONTINUES PHASE 2 DEVELOPMENT OF GEMCABENE FOR NAFLD/NASH.GEMPHIRE THERAPEUTICS INC - COMPANY AMENDS LOAN AGREEMENT WITH SVB TO PROVIDE ADDITIONAL FLEXIBILITY.GEMPHIRE - PHASE 2A PROOF-OF-CONCEPT STUDIES INVESTIGATING GEMCABENE FOR FAMILIAL PARTIAL LIPODYSTROPHY AND FOR PEDIATRIC NAFLD UNAFFECTED BY FDA REQUEST.  Full Article

Gemphire Announces Amended And Restated Gemcabene License Agreement With Pfizer
Monday, 6 Aug 2018 04:01pm EDT 

Aug 6 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE ANNOUNCES AMENDED AND RESTATED GEMCABENE LICENSE AGREEMENT WITH PFIZER INC..RESTATED LICENSE AGREEMENT WITH PFIZER COVERING GEMCABENE.GEMPHIRE THERAPEUTICS INC - AS AMENDED, PFIZER HAS RIGHT TO TERMINATE LICENSE IF FIRST COMMERCIAL SALE HAS NOT OCCURRED BY APRIL 2024.AMENDMENT INCLUDS EXTENDING DATE OF AGREED DEADLINE FOR FIRST COMMERCIAL SALE.  Full Article

Gemphire Therapeutics Announces Start Of First Nash Proof-Of-Concept Clinical Trial
Thursday, 21 Dec 2017 06:00am EST 

Dec 21 (Reuters) - Gemphire Therapeutics Inc ::GEMPHIRE THERAPEUTICS ANNOUNCES INITIATION OF ITS FIRST NASH PROOF-OF-CONCEPT CLINICAL TRIAL AND ITS DIFFERENTIATED NASH PROGRAM.GEMPHIRE THERAPEUTICS INC - NASH PROGRAM EXPECTED TO BE PHASE 2B READY BY YEAR-END 2018.GEMPHIRE THERAPEUTICS INC - PLANS TO LAUNCH A SECOND PHASE 2A PROOF-OF-CONCEPT TRIAL IN NASH EARLY IN 2018.  Full Article

Gemphire Therapeutics reports qtrly loss of $0.82‍​/shr
Monday, 13 Nov 2017 09:05am EST 

Nov 13 (Reuters) - Gemphire Therapeutics Inc :Gemphire Therapeutics Inc qtrly loss per share $0.82‍​.  Full Article

BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58

* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE